Sorafenib-induced destructive thyroiditis

Thyroid. 2010 Sep;20(9):1043-4. doi: 10.1089/thy.2010.0070.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Benzenesulfonates / adverse effects*
  • Benzenesulfonates / therapeutic use
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / surgery
  • Chronic Disease
  • Hepatitis B, Chronic / complications
  • Hepatitis B, Chronic / drug therapy
  • Humans
  • Iodine Radioisotopes
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / surgery
  • Male
  • Middle Aged
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Prednisone / therapeutic use
  • Propranolol / therapeutic use
  • Protein Kinase Inhibitors / adverse effects*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridines / adverse effects*
  • Pyridines / therapeutic use
  • Sorafenib
  • Technetium
  • Thyroiditis / chemically induced
  • Thyroiditis / diagnosis*

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Iodine Radioisotopes
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyridines
  • Niacinamide
  • Technetium
  • Propranolol
  • Sorafenib
  • Prednisone